title: [Incidence of metabolic syndrome in systemic lupus erythematosus and its influence by glucocorticoids].
abstract: OBJECTIVE
  To investigate the incidence and correlative factors of metabolic syndrome (MS) in patients with systemic lupus erythematosus (SLE).
  
  
  METHODS
  A total of 116 SLE patients and 115 controls were enrolled into the study. The incidence of MS, SLE disease activity index (SLEDAI) of patients with SLE combined with MS (MS-SLE) and patients without MS (n-MS-SLE), lupus characteristics, cumulative glucocorticoids, administration dose of glucocorticoids and hydroxychloroquine were compared between SLE group and the control group.
  
  
  RESULTS
  The incidence of MS of SLE group was obviously higher than that of the control (34.48% vs 14.78%, P < 0.05). The ratios of patients with lower HDL-C, higher TG and higher blood pressure in SLE group (50.86%, 56.03%, 46.55%) were higher than those in the controls (34.78%, 16.52%, 20.00%, all P < 0.05). MS-SLE group had significantly higher mean waist circumference, BMI, systolic blood pressure and diastolic blood pressure and lower HDL-C than n-MS-SLE group (all P < 0.05). No significant difference was found regarding duration of disease, renal involvement, ESR, C-reactive protein,high-sensitivity C-reactive protein, SLEDAI, cumulative and current glucocorticoids use in MS-SLE group and n-MS-SLE group. The ratio of patients taking hydroxychloroquine in n-MS-SLE group was higher than that of MS-SLE group (46.05% vs 15.00%, P < 0.05).
  
  
  CONCLUSIONS
  Patients with SLE has a higher incidence rate of MS. Hydroxychloroquine may reduce their MS incidence.
authors.affiliation: Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100032, China.
authors.forename: Sheng-yun
authors.initials: SY
authors.lastname: Liu
authors.forename: Jin-yan
authors.initials: JY
authors.lastname: Guo
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.forename: Zhang-suo
authors.initials: ZS
authors.lastname: Liu
authors.forename: Zhao-hui
authors.initials: ZH
authors.lastname: Zheng
authors.forename: Gen-yang
authors.initials: GY
authors.lastname: Cheng
authors.forename: Guan-min
authors.initials: GM
authors.lastname: Gao
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
authors.forename: Gui-zhi
authors.initials: GZ
authors.lastname: Liu
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Zeng
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D015994:Incidence; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D024821:Metabolic Syndrome / Q000209:etiology*; D008875:Middle Aged; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D006886:Hydroxychloroquine